Roger Perlmutter builds Eikon's pipeline with deal-making flurry, raising $106M more

Andrew Dunn

Senior Biopharma Correspondent

Eikon Therapeutics announced three business development deals on Thursday, effectively dropping in a pipeline of cancer drugs alongside more than $100 million in fresh funding …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Roger Perlmutter builds Eikon's pipeline with deal-making flurry, raising $106M more

Andrew Dunn

Senior Biopharma Correspondent

Sign up to read this article for free.

Vice President, Biology & Translational Research

Gondolabio

Palo Alto, CA, USA

Boehringer’s updated results in HER2-mutated lung cancer impress

Novavax responds to FDA’s trial ask, with Covid vaccine strain updates under scrutiny

Scholar Rock names new CEO, adds biotech veterans in C-suite rebuild

Merck KGaA to buy rare cancer biotech SpringWorks for $3.9B

GSK’s checkpoint blocker Jemperli cures biomarker-driven rectal cancer

Revolutionizing obesity treatment: Could mitochondria hold the key to unlocking fat-specific weight loss?

Roger Perl­mut­ter builds Eikon's pipeline with deal-mak­ing flur­ry, rais­ing $106M more

Senior Biopharma Correspondent

Sign up to read this article for free.

Gondolabio

Palo Alto, CA, USA

Roger Perlmutter builds Eikon's pipeline with deal-making flurry, raising $106M more